Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xbrane Biopharma AB ( (SE:XBRANE) ) has provided an announcement.
Xbrane Biopharma AB held an extra general meeting where several key resolutions were passed, including amendments to the articles of association to adjust share limits and a reverse share split to consolidate shares. The meeting also approved a reduction in share capital to cover losses and allocate to unrestricted equity, and authorized the board to issue shares, warrants, and convertibles to raise new capital and increase flexibility. These decisions are aimed at strengthening the company’s financial position and expanding its shareholder base, potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company operating in the biopharmaceutical industry, focusing on developing and manufacturing biosimilar drugs. The company aims to provide cost-effective alternatives to existing biologic therapies, targeting a global market with a growing demand for affordable healthcare solutions.
YTD Price Performance: 66.88%
Average Trading Volume: 14,073,901
Technical Sentiment Signal: Sell
Current Market Cap: SEK687.7M
Find detailed analytics on XBRANE stock on TipRanks’ Stock Analysis page.